If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take "immediate enforcement action," including assessing civil monetary penalties on Johnson & Johnson for intentionally overcharging 340B hospitals, the AHA said Aug. 28 in a letter to HRSA.
"J&J is yet again engaging in 340B vigilantism," AHA's General Counsel Chad Golder wrote. "J&J's adoption of this rebate model is yet another example of a drug company seeking to squeeze every possible penny from the hospitals and health systems that care for America's underserved patients."
On Aug. 23, J&J announced that it would be upending its approach to 340B pricing for two of its most popular products, Stelara and Xarelto. Historically, J&J offered upfront discounts to 340B hospitals when they purchase these drugs. Starting on Oct. 15, however, J&J will require all disproportionate share hospitals participating in the 340B Drug Pricing Program to purchase these drugs at full price and apply for a rebate from J&J. Under the new program, these hospitals will be required to submit certain data to J&J when they purchase the drugs at full price. After J&J verifies the drug's 340B status, it will send disproportionate share hospitals a rebate for the difference between the amount paid and the discounted 340B price.
AHA said that J&J's new policy is a fundamental shift in how the 340B program has operated for over 30 years and "could jeopardize patients' access to these drugs." In addition, disproportionate share hospitals, which already operate on the thinnest of margins, will be forced to develop pricey administrative mechanisms to make and track rebate requests.
"And J&J will essentially transform itself into the ultimate arbiter of whether a rebate should be approved and paid, with the likely consequence of J&J denying rebates to hospitals that they appropriately owe," AHA said. "While J&J may contend that this new policy is needed to improve program transparency, Congress did not permit drug companies to take the law into their own hands.... This new rebate policy — like the drug companies' contract pharmacy policies that preceded it — is a money-making scheme dressed up as a program integrity measure."
如果強生公司繼續實施破壞 340B 藥品定價計劃的計劃,單方面實施回扣模式,而不是長期存在的預付折扣模式,美國衛生資源和服務管理局 (HRSA) 應採取「立即執法行動」,包括對強生公司故意向 340B 醫院收取過高費用的行爲處以民事罰款,AHA 在 8 月 28 日致 HRSA 的一封信中表示。
AHA 總法律顧問 Chad Golder 寫道。「強生公司採用這種回扣模式是製藥公司試圖從爲美國服務不足的患者提供醫療服務的醫院和醫療系統榨取每一分錢的又一例子。」
8 月 23 日,強生公司宣佈將改變其兩種最受歡迎的產品 Stelara 和 Xarelto 的 340B 定價方法。從歷史上看,強生公司在購買這些藥品時會向 340B 醫院提供前期折扣。然而,從 10 月 15 日開始,強生公司將要求所有參與 340B 藥品定價計劃的不成比例份額醫院以全價購買這些藥品,並向強生公司申請回扣。根據新計劃,這些醫院在以全價購買藥品時必須向強生公司提交某些數據。在強生公司核實該藥品的 340B 狀態後,它將向不成比例份額醫院提供回扣,回扣金額爲支付金額與折扣後的 340B 價格之間的差額。
AHA 表示,強生公司的新政策是 340B 計劃 30 多年來運作方式的根本性轉變,「可能會危及患者獲得這些藥品的機會。」此外,利潤已經非常微薄的不成比例的醫院將被迫開發昂貴的行政機制來提出和跟蹤回扣請求。
「強生公司將基本上成爲是否應批准和支付回扣的最終仲裁者,其可能的後果是強生公司拒絕向他們應得的醫院提供回扣,」AHA 表示。「雖然強生公司可能認爲這項新政策是提高計劃透明度所必需的,但國會並沒有允許製藥公司自行制定法律……這項新的回扣政策——就像製藥公司之前的合同藥房政策一樣——是一種僞裝成計劃完整性措施的賺錢計劃。」